Tris Pharma Inc. v. Par Pharmaceutical Inc.
1:15-cv-00068
Overview
Parties
Defendant
Par Pharmaceutical Inc. Operating Company
Represented By
5 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Par Pharmaceutical Companies Inc. Operating Company
Represented By
2 Attorneys ListedRichards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Richards, Layton & Finger, PA
Richards, Layton & Finger, PA, One Rodney Square
Plaintiff
Tris Pharma Inc. Operating Company
Represented By
3 Attorneys ListedMorris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Morris, Nichols, Arsht & Tunnell LLP
1201 North Market Street, P.O. Box 1347
Court & Judges
Court
District Court, D. Delaware (ded)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360Β° RadarMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
Tris Pharma Inc. v. Actavis Laboratories FL Inc.
Patents Involved
There are 5 patents involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8062667
Modified release formulations containing drug-ion exchange resin complexes
|
Filed: 2007-03-15
Issued: 2011-11-22
|
Active (2.4 yrs remaining)
+745d PTA
Expires: 2029-03-29
|
|
|
US8827903
Modular tool heads for use with circular surgical instruments
|
Filed: 2011-07-13
Issued: 2014-09-09
|
Active (5.2 yrs remaining)
+206d PTA
Expires: 2032-02-04
|
|
|
US8465765
Orally effective methylphenidate extended release powder and aqueous suspension product
|
Filed: 2012-09-12
Issued: 2013-06-18
|
Active (5.8 yrs remaining)
Expires: 2032-09-12
|
|
|
US8563033
Orally effective methylphenidate extended release powder and aqueous suspension product
|
Filed: 2013-05-30
Issued: 2013-10-22
|
Active (6.5 yrs remaining)
Expires: 2033-05-30
|
|
|
US8778390
Orally effective methylphenidate extended release powder and aqueous suspension product
|
Filed: 2013-09-03
Issued: 2014-07-15
|
Active (6.8 yrs remaining)
Expires: 2033-09-03
|
Patent Enforceability & Injunction Risk Assessment
Active Threat β Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.
High PTA (+745 days) / Cellect Scrutiny β Over 745 days of PTA awarded. Susceptible to In re Cellect double patenting invalidation if continuation patents in the same family expire earlier.
Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).